Figure 6.

Genistein enhances the antitumor effects of miR-223 inhibitor in vivo. A. BxPC-3 GR cells were subcutaneously injected into the right flank of five-week-old male nude mice. After 2 weeks for palpable subcutaneous tumors to form, themice were separated into four groups (each group, n=5), namely vehicle (100 μl control antagomir, diluted in PBS) by injection to intratumor), genistein alone, miR-223 inhibitor alone, and genistein plus miR-223 inhibitor. Genistein was given by gavage (15 mg/kg daily for 20 days). The control antagomir or 100 μL miR-223 inhibitor (diluted in PBS at 2 mg/ml) was injected twice a week for 3 weeks by way of multiple-center intratumor injection, separately. The tumor size was measured with a caliper every 5 days. Tumor volume was calculated as length × width × height/2. B. Mice of each group were killed after three weeks injections, and the xenografted tumors were excised and examined Western blotting. The expression of Notch-1 and EMT markers was measured by Western blotting in mice tumors.